Company / Total Assets
Akebia Therapeutics, Inc. Total Assets History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$376.6M
FY2025
5-year range
$220.7M / $525.5M
FY2021-FY2025
Trend
+70.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets returned to growth in FY2025 after 6 years of decline, reaching $377M.
Based on SEC 10-K filings.
$377M in FY2025 with a 10-year CAGR of +10.2%.
Improved from $242M to $377M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- +1.9%
- 5-Year CAGR
- -10.2%
- 10-Year CAGR
- +10.2%
Key checks
Key Insights
- 5-year CAGR of -10.2%, indicating a declining trend.
- In FY2025, total assets increased 70.6% year-over-year.
- Peak total assets was recorded in FY2018.
- Lowest total assets in the period was in FY2014.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $376.6M | +70.6% |
| FY2024 | $220.7M | -8.7% |
| FY2023 | $241.7M | -32.1% |
| FY2022 | $356.1M | -32.3% |
| FY2021 | $525.5M | -18.4% |
| FY2020 | $644.1M | -16.5% |
| FY2019 | $771.2M | -22.6% |
| FY2018 | $996.5M | +597.2% |
| FY2015 | $142.9M | +28.8% |
| FY2014 | $111.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026